Phase III trial with Ninlaro meets primary endpoint as first line maintenance treatment of multiple myeloma.- Takeda
Takeda Pharmaceutical will present positive results from TOURMALINE-MM4, a Phase III, randomized clinical trial evaluating the effect of single-agent oral Ninlaro (ixazomib) as a first-line maintenance therapy in… read more.